Immediate breast reconstruction in the high-risk adjuvant setting.
High-dose chemotherapy with autologous stem cell support (or bone marrow transplantation) in the treatment of primary breast cancer has been developed in the hopes of increasing survival among patients traditionally regarded as "high risk". These patients have locally advanced disease (stage IIB or higher) and have a greater than 50% risk of developing systemic illness. This report addresses the issue of whether reconstructive breast surgery can be offered to high-risk patients. It is hoped that as survival among women with advanced or high-stage primary breast cancer increases, options for immediate breast reconstruction can be routinely offered.
Wey
P D
PD
Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick 08901-0019, USA.
Highstein
J B
JB
Borah
G L
GL
D016026:Bone Marrow Transplantation; D018427:Breast Implants; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016462:Mammaplasty / Q000379:methods*; D015411:Mastectomy, Modified Radical; D008875:Middle Aged; D009367:Neoplasm Staging; D012086:Reoperation; D015625:Tissue Expansion Devices